261 related articles for article (PubMed ID: 35654979)
21. RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.
Snead NM; Rossi JJ
Nucleic Acid Ther; 2012 Jun; 22(3):139-46. PubMed ID: 22703279
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of chemically modified siRNA: Recent trends.
Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
[TBL] [Abstract][Full Text] [Related]
23. RNA interference in the era of nucleic acid therapeutics.
Jadhav V; Vaishnaw A; Fitzgerald K; Maier MA
Nat Biotechnol; 2024 Mar; 42(3):394-405. PubMed ID: 38409587
[TBL] [Abstract][Full Text] [Related]
24. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
25. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
26. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
27. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
28. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
[TBL] [Abstract][Full Text] [Related]
29. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles.
Nakayama T; Butler JS; Sehgal A; Severgnini M; Racie T; Sharman J; Ding F; Morskaya SS; Brodsky J; Tchangov L; Kosovrasti V; Meys M; Nechev L; Wang G; Peng CG; Fang Y; Maier M; Rajeev KG; Li R; Hettinger J; Barros S; Clausen V; Zhang X; Wang Q; Hutabarat R; Dokholyan NV; Wolfrum C; Manoharan M; Kotelianski V; Stoffel M; Sah DW
Mol Ther; 2012 Aug; 20(8):1582-9. PubMed ID: 22850721
[TBL] [Abstract][Full Text] [Related]
30. Effect of nanoparticle conjugation on gene silencing by RNA interference.
Singh N; Agrawal A; Leung AK; Sharp PA; Bhatia SN
J Am Chem Soc; 2010 Jun; 132(24):8241-3. PubMed ID: 20518524
[TBL] [Abstract][Full Text] [Related]
31. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics.
Hou B; Qin L; Huang L
Biochem Biophys Res Commun; 2023 Feb; 644():85-94. PubMed ID: 36640667
[TBL] [Abstract][Full Text] [Related]
32. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
33. Construction of simple and efficient siRNA validation systems for screening and identification of effective RNAi-targeted sequences from mammalian genes.
Tsai WH; Chang WT
Methods Mol Biol; 2014; 1101():321-38. PubMed ID: 24233788
[TBL] [Abstract][Full Text] [Related]
34. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
Li T; Wu M; Zhu YY; Chen J; Chen L
Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
[TBL] [Abstract][Full Text] [Related]
35. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.
Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S
Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020
[TBL] [Abstract][Full Text] [Related]
36. A modular platform for targeted RNAi therapeutics.
Kedmi R; Veiga N; Ramishetti S; Goldsmith M; Rosenblum D; Dammes N; Hazan-Halevy I; Nahary L; Leviatan-Ben-Arye S; Harlev M; Behlke M; Benhar I; Lieberman J; Peer D
Nat Nanotechnol; 2018 Mar; 13(3):214-219. PubMed ID: 29379205
[TBL] [Abstract][Full Text] [Related]
37. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.
Guzman-Aranguez A; Loma P; Pintor J
Br J Pharmacol; 2013 Oct; 170(4):730-47. PubMed ID: 23937539
[TBL] [Abstract][Full Text] [Related]
38. Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I; Kang CS; Han J
Exp Mol Med; 2023 Jul; 55(7):1283-1292. PubMed ID: 37430086
[TBL] [Abstract][Full Text] [Related]
39. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
40. Gene-silencing potency of symmetric and asymmetric lipid-conjugated siRNAs and its correlation with dicer recognition.
Kubo T; Yanagihara K; Sato Y; Nishimura Y; Kondo S; Seyama T
Bioconjug Chem; 2013 Dec; 24(12):2045-57. PubMed ID: 24274056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
